Maiden Pharma responsible for deaths of 70 children from acute kidney injury: Gambian Parliamentary committee
"All the cases of AKI are linked to the consumption of contaminated medical products...manufactured by Maiden Pharmaceuticals," the committee's chairperson Amadou Camara said in a statement to parliament.
Dakar: A parliamentary committee in Gambia said that India-based drug maker Maiden Pharmaceuticals Ltd was responsible for the deaths of at least 70 children from acute kidney injury and called on the government to pursue legal action.Maiden's managing director, Naresh Kumar Goyal, did not immediately respond to calls and messages from Reuters on Tuesday.The World Health Organization in...
Login or Register to read the full article
Dakar: A parliamentary committee in Gambia said that India-based drug maker Maiden Pharmaceuticals Ltd was responsible for the deaths of at least 70 children from acute kidney injury and called on the government to pursue legal action.
Maiden's managing director, Naresh Kumar Goyal, did not immediately respond to calls and messages from Reuters on Tuesday.
The World Health Organization in October said four medicinal syrups made by Maiden and imported by a local wholesaler were likely linked to the deaths, which have shocked the West African country since July. The drugs were pulled from the shelves and Maiden's production licence in India was suspended.
After its investigation, Gambia's select committee on health reached a similar conclusion.
"All the cases of AKI are linked to the consumption of contaminated medical products...manufactured by Maiden Pharmaceuticals," the committee's chairperson Amadou Camara said in a statement to parliament.
Goyal on Friday told Reuters that his company had done no wrong.
The WHO in October said that lab analysis confirmed "unacceptable" amounts of diethylene glycol and ethylene glycol in the medicines made by Maiden, which can be toxic and lead to acute kidney injury.
Earlier this month India told the WHO that tests of samples from the same batches of syrups that were sent to Gambia were compliant with government specifications.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd